MapLight Therapeutics, Inc. MPLT
- betovumeline — Schizophrenia Phase 2
- betovumeline — Alzheimer's Disease Psychosis Phase 2
- ML-055 Preclinical
- ML-021 — Parkinson's Disease Preclinical
Home › Targets › M4 muscarinic receptor
M4 muscarinic receptor (1 companies · 4 programs)
Companies with an active program directed at M4 muscarinic receptor.